TRUE Private Wealth Advisors Grows Stock Holdings in Eli Lilly and Company $LLY

TRUE Private Wealth Advisors lifted its stake in Eli Lilly and Company (NYSE:LLY) by 7.2% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,366 shares of the company’s stock after purchasing an additional 497 shares during the quarter. Eli Lilly and Company comprises approximately 0.6% of TRUE Private Wealth Advisors’ holdings, making the stock its 28th largest position. TRUE Private Wealth Advisors’ holdings in Eli Lilly and Company were worth $5,742,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. PNC Financial Services Group Inc. increased its holdings in shares of Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after acquiring an additional 50,002,551 shares in the last quarter. Nuveen LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. lifted its position in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares during the period. Assenagon Asset Management S.A. lifted its position in Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock valued at $1,154,508,000 after purchasing an additional 765,010 shares during the period. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock worth $4,808,443,000 after acquiring an additional 682,203 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 0.9%

LLY opened at $1,030.49 on Wednesday. The stock has a market cap of $974.21 billion, a price-to-earnings ratio of 67.35, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The firm’s fifty day moving average is $838.20 and its 200 day moving average is $782.36. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,040.72.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. During the same period last year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. The ex-dividend date of this dividend is Friday, November 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 29.35%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Loop Capital set a $950.00 price objective on shares of Eli Lilly and Company in a report on Monday, November 10th. UBS Group lifted their price target on shares of Eli Lilly and Company from $895.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. HSBC raised their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,020.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.